Mark Schoenberg
Tracked across 2 events · 12 articles · First seen Jun 14, 2026 · Last active Jul 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Mark Schoenberg, the Chief Medical Officer of UroGen Pharma Ltd., sold shares of the company's common stock in multiple transactions, reducing his direct holdings but still maintaining a significant ownership position. These sales are described as routine liquidity management.
Jun 14, 2026 · 6 articles
Regulatory
Impact: As Chief Medical Officer, Schoenberg commented on the IND clearance, highlighting the potential of UGN-501.
Jul 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Mark Schoenberg live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard